Guy Neild
Guy's Hospital
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Guy Neild.
The Lancet | 1983
Susan P. Fisher-Hoch; G. Lloyd; G.S. Platt; D.I.H. Simpson; Guy Neild; A.J. Barrett
Patients with severe viral infections such as Lassa or Ebola may be denied adequate laboratory investigations because of justifiable fears among laboratory staff. This study in monkeys was designed to provide comprehensive haematological and biochemical monitoring in a contained environment during all stages of Ebola infection. Marked neutrophilia, depletion of lymphocytes, and early failure of platelet aggregation preceded a consumption coagulopathy with a microangiopathic haemolytic anaemia, thrombocytopenia, and failure of prostacyclin production by vascular endothelium. Liver dysfunction was moderate but in conjunction with the dehydration and hypoalbuminaemia could be expected to precipitate renal failure and shock. It seems reasonable to anticipate successful patient support with a patient management isolator and treatment with platelet transfusions, fresh frozen plasma, and possibly prostacyclin when haemostasis is defective during this otherwise self-limiting illness.
The Lancet | 1985
D. Taube; D. Gwyn Williams; B. Hartley; C.J. Rudge; Guy Neild; Js Cameron; C.S. Ogg; Kenneth I. Welsh
In a retrospective study of 60 renal-transplant patients immunosuppressed with cyclosporin no specific clinical features differentiated allograft dysfunction responsive to anti-rejection therapy from dysfunction responsive to reduction in cyclosporin dosage. Histologically, allograft dysfunction responsive to anti-rejection therapy was strongly associated with diffuse interstitial infiltration by mononuclear cells, oedema, and haemorrhage, vascular endothelial-cell proliferation, and infiltration of arterial walls by mononuclear cells. Arteriolar medial hypertrophy and hyalinosis were more commonly found in biopsy specimens from allografts with dysfunction responsive to reduction in cyclosporin dose than in those with dysfunction responsive to anti-rejection therapy and those with stable or improving function. Whole-blood cyclosporin concentrations were significantly lower in patients with dysfunction reversed by anti-rejection therapy than in those with dysfunction reversed by reduction in cyclosporin dose or in those with stable function. There was, however, considerable overlap between these groups, so that individual cyclosporin measurements were of little diagnostic value.
The Lancet | 1986
Guy Neild; Mary Anderson; S. Hawes; B.T. Colvin
The Lancet | 1999
Jan Clement; Guy Neild; Sylvia Lemos Hinrichsen; José Angelo Crescente; Marc Van Ranst
The Lancet | 1983
Susan P. Fisher-Hoch; Graham Lloyd; C.L.R. Bartlett; Guy Neild
The Lancet | 1991
ChristopherJ Meade; Susan Metcalfe; Rosamund Svvennsen; Neville V. Jamieson; Christopher J. E. Watson; R. Y. Calne; Gerhard Kleber; Guy Neild
The Lancet | 1981
Guy Neild
The Lancet | 1979
Guy Neild; Trevor Southee
The Lancet | 1993
Guy Neild
The Lancet | 1983
SusanP. Fisher-Hoch; Graham Lloyd; C.L.R. Bartlett; Guy Neild